Procedure for reviewing new drug submissions

1. Inform JFC support and DTC Formulary Pharmacists of all submissions. Submission to be added to the JFC Planner (uploaded weekly onto JFC website)

2. Does the application have a NICE Technology Assessment (TA) approval or funding from the Cancer drugs fund?
   - Y: Application to be implemented locally
   - N: Next step

3. Will all prescribing be retained in a single Trust?*
   - Y: Application heard at local DTC
   - N: Next step

4. Is a NICE Technology Assessment (TA) planned?
   - Y: Has the company provided a compassionate use scheme that includes:
     - Pre-NICE funding
     - 90 days post-NICE funding
     - Unconditional funding in the event that the patient does not meet NICE criteria
   - N: Raise under AOB at next JFC meeting. Is the Committee in favour of reviewing the application?
   - Y: Application heard at JFC or local DTC‡
   - N: Specialist DTC decision sent to JFC for ratification

5. Is the application particularly relevant to a specialist (tertiary referral) Trust?
   - Y: Consult with JFC support; application heard at JFC or local DTC‡
   - N: Application to be heard at JFC

* Established collaboratively between DTC formulary pharmacists and JFC support
‡ A local DTC may be chosen based on local expertise and capacity. For example, the JFC would approach MEH to consider a new ophthalmologic preparation, even if the application originated from a different Trust (e.g. RFH).